A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

March 4, 2025

Study Completion Date

March 4, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

REGN17092

Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

DRUG

Matching Placebo

Single ascending IV or SC administration per the protocol

Trial Locations (1)

UZ Leuven Gasthuisberg Campus, Leuven

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT05923424 - A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults | Biotech Hunter | Biotech Hunter